214 related articles for article (PubMed ID: 11178117)
1. The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma.
Brouwer R; Pruijn GJ; van Venrooij WJ
Arthritis Res; 2001; 3(2):102-6. PubMed ID: 11178117
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies directed to novel components of the PM/Scl complex, the human exosome.
Brouwer R; Vree Egberts WT; Hengstman GJ; Raijmakers R; van Engelen BG; Seelig HP; Renz M; Mierau R; Genth E; Pruijn GJ; van Venrooij WJ
Arthritis Res; 2002; 4(2):134-8. PubMed ID: 11879549
[TBL] [Abstract][Full Text] [Related]
3. The human exosome and disease.
Staals RH; Pruijn GJ
Adv Exp Med Biol; 2011; 702():132-42. PubMed ID: 21713683
[TBL] [Abstract][Full Text] [Related]
4. The human exosome and disease.
Staals RH; Pruijn GJ
Adv Exp Med Biol; 2010; 702():132-42. PubMed ID: 21618880
[TBL] [Abstract][Full Text] [Related]
5. PM1-Alpha ELISA: the assay of choice for the detection of anti-PM/Scl autoantibodies?
Mahler M; Fritzler MJ
Autoimmun Rev; 2009 Mar; 8(5):373-8. PubMed ID: 19103309
[TBL] [Abstract][Full Text] [Related]
6. The changing landscape of the clinical value of the PM/Scl autoantibody system.
Mahler M; Fritzler MJ
Arthritis Res Ther; 2009; 11(2):106. PubMed ID: 19351430
[TBL] [Abstract][Full Text] [Related]
7. The yeast exosome and human PM-Scl are related complexes of 3' --> 5' exonucleases.
Allmang C; Petfalski E; Podtelejnikov A; Mann M; Tollervey D; Mitchell P
Genes Dev; 1999 Aug; 13(16):2148-58. PubMed ID: 10465791
[TBL] [Abstract][Full Text] [Related]
8. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome.
Raijmakers R; Renz M; Wiemann C; Egberts WV; Seelig HP; van Venrooij WJ; Pruijn GJ
Arthritis Rheum; 2004 Feb; 50(2):565-9. PubMed ID: 14872500
[TBL] [Abstract][Full Text] [Related]
9. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations.
Oddis CV; Okano Y; Rudert WA; Trucco M; Duquesnoy RJ; Medsger TA
Arthritis Rheum; 1992 Oct; 35(10):1211-7. PubMed ID: 1418007
[TBL] [Abstract][Full Text] [Related]
10. C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome.
Schilders G; Egberts WV; Raijmakers R; Pruijn GJ
Arthritis Rheum; 2007 Jul; 56(7):2449-54. PubMed ID: 17599775
[TBL] [Abstract][Full Text] [Related]
11. [PM-Scl antibody positive systemic sclerosis associated with inclusion-body myositis].
Kim S; Genth E; Krieg T; Hunzelmann N
Z Rheumatol; 2005 Oct; 64(7):499-502. PubMed ID: 16244833
[TBL] [Abstract][Full Text] [Related]
12. The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort.
Lazzaroni MG; Marasco E; Campochiaro C; DeVries-Bouwstra J; Gonzalez-Perez MI; Rojas-Serrano J; Hachulla E; Zanatta E; Barsotti S; Furini F; Triantafyllias K; Abignano G; Truchetet ME; De Luca G; De Langhe E; Hesselstrand R; Ingegnoli F; Bertoldo E; Smith V; Bellando-Randone S; Poormoghim H; Colombo E; Ceribelli A; Furloni A; Zingarelli S; Cavazzana I; Franceschini F; Del Galdo F; Denton CP; Cavagna L; Distler O; Allanore Y; Airò P;
Rheumatology (Oxford); 2021 Nov; 60(11):5028-5041. PubMed ID: 33580257
[TBL] [Abstract][Full Text] [Related]
13. Scleroderma/polymyositis overlap syndromes and their immunologic markers.
Jablonska S; Chorzelski TP; Blaszczyk M; Jarzabek-Chorzelska M; Kumar V; Beutner EH
Clin Dermatol; 1992; 10(4):457-72. PubMed ID: 1303810
[No Abstract] [Full Text] [Related]
14. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.
Hanke K; Brückner CS; Dähnrich C; Huscher D; Komorowski L; Meyer W; Janssen A; Backhaus M; Becker M; Kill A; Egerer K; Burmester GR; Hiepe F; Schlumberger W; Riemekasten G
Arthritis Res Ther; 2009; 11(1):R22. PubMed ID: 19220911
[TBL] [Abstract][Full Text] [Related]
15. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl.
Marguerie C; Bunn CC; Copier J; Bernstein RM; Gilroy JM; Black CM; So AK; Walport MJ
Medicine (Baltimore); 1992 Nov; 71(6):327-36. PubMed ID: 1435228
[TBL] [Abstract][Full Text] [Related]
16. [Anti PM-Scl antibodies. Study of prevalence and of meaning].
Gaudin C; Fortenfant F; Adoue D; Beyne-Rauzy O
Rev Med Interne; 2006 Sep; 27(9):665-70. PubMed ID: 16797795
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the specificity of anti-PM-Scl autoantibodies.
Ge Q; Wu Y; Trieu EP; Targoff IN
Arthritis Rheum; 1994 Oct; 37(10):1445-52. PubMed ID: 7945469
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis.
Villalta D; Morozzi G; Tampoia M; Alpini C; Brusca I; Salgarolo V; Papisch W; Bizzaro N
Clin Chim Acta; 2010 May; 411(9-10):710-3. PubMed ID: 20138166
[TBL] [Abstract][Full Text] [Related]
19. Anti-PM/Scl-100 and anti-RNA-polymerase III antibodies in scleroderma.
Maes L; Blockmans D; Verschueren P; Westhovens R; De Beéck KO; Vermeersch P; Van den Bergh K; Burlingame RW; Mahler M; Bossuyt X
Clin Chim Acta; 2010 Jul; 411(13-14):965-71. PubMed ID: 20346932
[TBL] [Abstract][Full Text] [Related]
20. Anti-PM-Scl antibody in patients with systemic sclerosis.
Koschik RW; Fertig N; Lucas MR; Domsic RT; Medsger TA
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S12-6. PubMed ID: 22261302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
